Navigation Links
Nektar Therapeutics Announces Second Quarter 2008 Results
Date:8/6/2008

,727) (4,264)

Increase (decrease) in accrued

compensation (3,676) 954

Increase (decrease) in accrued

expenses to contract manufacturers (40,444) -

Increase (decrease) in accrued

expenses 9,099 (1,600)

Increase (decrease) in interest

payable 7 (708)

Increase (decrease) in deferred

revenue (5,321) 16,952

Increase (decrease) in other

liabilities (1,222) (380)

Net cash used in operating activities (96,425) (14,687)

Cash flows from investing activities:

Purchases of investments (334,685) (273,540)

Maturities of investments 369,337 353,171

Sales of investments 28,590 -

Purchases of property and equipment (10,349) (11,765)

Net cash provided by investing

activities 52,893 67,866

Cash flows used in financing

activities:

Proceeds from issuance of common

stock 383 2,708

Payments of loan and capital lease

obligations (1,151) (823)

Repayments of convertible

subordinated notes - (36,026)

Net cash used in financing activities (768) (34,141)

Effect of exchange rates on cash and

cash equivalents (164) 58

Net increase (decrease) in cash and

cash equivalents $(44,464) $19,096

Cash and cash equivalents at

beginning of period $76,293 $63,760

Cash and cash equivalents at end of

period $31,829 $82,856


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
2. Nektar Therapeutics Announces First Quarter 2008 Results
3. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
4. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
5. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
7. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
8. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
9. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
10. Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets
11. InteKrin Therapeutics Announces $20 Million Series C Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Renal artery stenting to open blockages in ... historically been excluded from modern clinical trials, according ... in Catheterization and Cardiovascular Interventions today ... (SCAI). , University Hospitals Case Medical Center,s Sahil ... Professor of Medicine, Case Western Reserve University School ...
(Date:8/22/2014)... August 22, 2014 Home Care ... in-home care for seniors, is proud to announce the ... The upcoming webinar will feature Dr. Suzanne Steinbaum, attending ... Hill Hospital in New York City, National Spokesperson for ... The webinar will cover the issues surrounding women and ...
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- Many children get ... vaccination, but there are a number of ways that ... an expert suggests. The first step is to ... vaccinations help protect their health, said Rita John, director ... Columbia University School of Nursing in New York City. ...
(Date:8/22/2014)... few years, several breakthrough treatments have become available ... may benefit from these treatments can be pre-identified ... cancer. For example, patients whose lung cancer is ... significant benefit from the drug crizotinib, which targets ... attempting to replicate this success by matching different ...
(Date:8/22/2014)... who need surgery for facial pain caused by trigeminal ... used, reports a study in the September issue of ... Congress of Neurological Surgeons . The journal is ... part of Wolters Kluwer Health . , Percutaneous ... lower cost than other types of surgical treatments for ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 3Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Simple Steps Make Shots Less Scary for Kids, Nurse Says 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 3Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 4Health News:More common procedures for painful facial tics carry high costs, reports study in Neurosurgery 2
... Hospira, Inc. (NYSE: HSP ), a leading global ... host a conference call to discuss its second-quarter 2009 results on ... , , The company will release its second-quarter 2009 results ... conference call. , , A live webcast of the ...
... military readiness, harms the health of soldiers and veterans, ... of Defense and Veterans Affairs, these agencies should implement ... goal of a tobacco-free military, says a new report ... phase in a ban on tobacco use in the ...
... Ormco Corporation, a subsidiary of Danaher Corporation (NYSE: ... jury verdict in its patent infringement case against Align Technology, ... to straighten teeth. The jury unanimously found that Align,s ... a patent held by Ormco. The claims at issue ...
... 26 Warner Chilcott Limited announced today that it will ... Meeting") and a Special Court-Ordered Meeting of Shareholders (the "Special ... the Company,s shareholders will be asked to vote in favor ... Company from Bermuda to Ireland. Subject to shareholder approval ...
... Calif., June 26 Align Technology, Inc. (Nasdaq: ... against Align in a lawsuit brought by Ormco Corporation (Ormco) ... for the Central District of California (District Court). Ormco alleged ... non-infringement, invalidity, as well as unenforceability of the patent. ...
... R.I., June 26 CVS Caremark (NYSE: ... been named as one of the nation,s leading corporations for innovative ... their families to make better choices about their own health and ... ) , , CVS Caremark received the ...
Cached Medicine News:Health News:DOD, VA should take stronger steps to combat tobacco use in military, veteran populations 2Health News:DOD, VA should take stronger steps to combat tobacco use in military, veteran populations 3Health News:Jury Renders Verdict for Ormco - Align's Invisalign(R) Product Infringes Ormco Patent 2Health News:Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders 2Health News:Align Technology Announces Jury Verdict in Patent Litigation With Ormco Corporation 2Health News:CVS Caremark Recognized with Gold Award from National Business Group on Health for Promoting Healthy Lifestyles for Employees 2Health News:CVS Caremark Recognized with Gold Award from National Business Group on Health for Promoting Healthy Lifestyles for Employees 3
(Date:8/22/2014)... 2014 Research and Markets  has announced ... Opportunities, Tools & Technologies" report to their offering. ... research products or you wish to expand your product ... market is. The authors know you want to make ... scientists, to generate improved revenues and take market share ...
(Date:8/22/2014)... Aug. 22, 2014 MC Medical, a subsidiary of ... Columbus, OH medical device company, have ... laparoscopic and robotic visualization system in Japan ... sale in Japan in the latter ... and an extensive product portfolio in endoscopic surgery market in ...
(Date:8/22/2014)... , Aug. 22, 2014   Zacks Equity Research highlights ... of the Day and Panera (Nasdaq: PNRA - Free Report ... Research provides analysis on Amicus Therapeutics (Nasdaq: FOLD - Free ... Shire (Nasdaq: SHPG - Free Report ). Here ... Bull of the Day : The biotech bull ...
Breaking Medicine Technology:Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6
... Designed in collaboration with Dr. George ... the Ojemann Cortical Stimulator is the ... procedures. This portable, constant current unit ... settings suitable for use in the ...
... Integra Epilepsy cortical strip electrodes are ... intracranial placement through a burr hole. ... tunneling and enables quick and secure ... Like all Integra Epilepsy electrode designs, ...
...
... URISYS 2400 is designed for laboratories looking ... and convenience in system operation in terms ... and extended calibration and on-board stability., ... system providing enhanced walk-away capability for medium ...
Medicine Products: